PMID- 30973890
OWN - NLM
STAT- In-Data-Review
LR  - 20190503
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 4
DP  - 2019
TI  - The prognostic value of CXC subfamily ligands in stage I-III patients with
      colorectal cancer.
PG  - e0214611
LID - 10.1371/journal.pone.0214611 [doi]
AB  - OBJECTIVE: To investigate the value of CXC subfamily ligands in stage I-III
      patients with colorectal cancer, in order to find a new predictor for CRC
      patients. METHODS: We used Gene Expression Omnibus (GEO) database to collect the 
      gene expression of CXC subfamily ligands and corresponding clinical data. The
      survival analysis was performed by "survival" package of Rsoftware. The CRC
      patients' DFS and the relationship between the expression levels of CXC subfamily
      ligands were evaluated by the univariate Cox regression analysis. RESULTS: By
      using microarray data, there were 14 CXC subfamily ligands identified from
      dataset GSE39582. Seven CXC subfamily ligands were significantly correlated with 
      DFS in CRC patients. (p<0.05),including CXCL1, CXCL3, CXCL9, CXCL10, CXCL11,
      CXCL13, and CXCL14. From multivariate Cox regression analyze, four CXC subfamily 
      ligands (CXCL9, CXCL10, CXCL11, and CXCL13) were significantly associated with
      CRC patients' DFS (all p<0.05). Three CXC subfamily ligands (CXCL10, CXCL11, and 
      CXCL13) were significantly associated with CRC patients' Overall survival (OS)
      (all p<0.05). Both CXCL11 and CXCL13 had the similar prediction values for DFS
      and OS. CONCLUSION: There were seven CXC subfamily ligands were significantly
      correlated with DFS in CRC patients. Different expression level of four CXC
      subfamily ligands (CXCL9, CXCL10, CXCL11, and CXCL13) and Three CXC subfamily
      ligands (CXCL10, CXCL11, and CXCL13) were related to CRC patients' DFS and OS.
      There are still needs more experiments to confirm our conclusions. Next step we
      will make animal experiment about the genes in order to verified the predictive
      value of the CXC subfamily ligands.
FAU - Li, Xiangde
AU  - Li X
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi
      Medical University, Nanning, Guangxi, China.
FAU - Zhong, Qiulu
AU  - Zhong Q
AUID- ORCID: http://orcid.org/0000-0002-8600-4103
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi
      Medical University, Nanning, Guangxi, China.
FAU - Luo, Danjing
AU  - Luo D
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi
      Medical University, Nanning, Guangxi, China.
FAU - Du, Qinghua
AU  - Du Q
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi
      Medical University, Nanning, Guangxi, China.
FAU - Liu, Wenqi
AU  - Liu W
AUID- ORCID: http://orcid.org/0000-0003-4986-1234
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi
      Medical University, Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20190411
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
PMC - PMC6459597
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/04/12 06:00
MHDA- 2019/04/12 06:00
CRDT- 2019/04/12 06:00
PHST- 2018/12/31 00:00 [received]
PHST- 2019/03/17 00:00 [accepted]
PHST- 2019/04/12 06:00 [entrez]
PHST- 2019/04/12 06:00 [pubmed]
PHST- 2019/04/12 06:00 [medline]
AID - 10.1371/journal.pone.0214611 [doi]
AID - PONE-D-18-36441 [pii]
PST - epublish
SO  - PLoS One. 2019 Apr 11;14(4):e0214611. doi: 10.1371/journal.pone.0214611.
      eCollection 2019.